Business Context and Reporting Period
This Form 6-K filing by GSK plc (GSK) reports a transaction in the company's own shares. The filing date is April 16, 2025, covering share purchases executed on April 15, 2025. The transaction was conducted through Citigroup Global Markets Limited as part of an existing non-discretionary buyback agreement entered into on February 24, 2025.
Key Financial Metrics
The filing details a specific share repurchase event rather than comprehensive financial results. Key metrics for the transaction include:
- Shares Purchased: 914,000 ordinary shares.
- Price Range: Lowest price paid was 1,327.50 GBp; highest price paid was 1,354.50 GBp.
- Average Price: Volume-weighted average price paid was 1,345.41 GBp.
- Treasury Shares: Following this purchase, GSK holds 198,295,404 ordinary shares in treasury.
- Shares in Issue: 4,116,939,751 ordinary shares (excluding treasury shares).
- Voting Rights: Total voting rights are 4,116,939,751.
The filing text does not provide clear values for revenue, profit, cash flow, margins, or debt levels, as this document is limited to reporting the share transaction.
Material Changes
Since the commencement of the buyback agreement on February 24, 2025, the Company has purchased a total of 29,225,101 ordinary shares. The purchase reported in this filing increased the total treasury share count to approximately 198.3 million. There are no other material changes to the company's financial position or operations disclosed in this specific filing.
Guidance, Outlook, and Risks
The filing contains a standard cautionary statement regarding forward-looking statements. GSK notes that projections are subject to risks and uncertainties that may cause actual results to differ materially. Specific risk factors are referenced as being described on pages 277 to 285 of the GSK 2024 Annual Report on Form 20-F. No new guidance or management commentary regarding future financial performance is provided in this document.
Important Facts for Investors
- Verify the total number of voting rights (4,116,939,751) for calculating disclosure thresholds under the Financial Conduct Authority's rules.
- Confirm the cumulative buyback volume of 29,225,101 shares since February 24, 2025.
- Note that the purchased shares are held as Treasury shares and do not carry voting rights.
- Review the GSK 2024 Annual Report on Form 20-F for detailed risk factors referenced in the cautionary statement.